WS #3106

Geopolitical tensions have escalated further, with Iran formally rejecting the U.S. ceasefire offer and demanding sovereignty over the Strait of Hormuz, directly contradicting earlier de-escalation signals and reinforcing supply disruption risks. This is corroborated by multiple sources, including CNBC and Iranian military statements, indicating a hardening stance. Concurrently, Ukrainian drone attacks on Russian oil infrastructure continue, with the Primorsk terminal reportedly resuming operations after a strike, suggesting ongoing but contained disruptions. The previous synthesis highlighted accelerating oil supply risks; this window confirms escalation, with Iran's rejection adding a sovereign control dimension beyond mere threats. In corporate news, mixed signals persist. Corcept Therapeutics (CORT) stock soared after FDA approval for a cancer treatment, a bullish development for biotech. Conversely, UBS lowered its price target for Braze (BRZE) despite maintaining a Buy rating, a bearish move for software. Comstock (LODE) shares rose on strong Q4 results, indicating positive micro-cap momentum. The tech sector shows slight gains in real-time quotes (META up 0.23%, GOOGL up 0.25%), offsetting earlier layoff concerns, while broader indices (SPY flat, QQQ down 0.09%) reflect muted sentiment amid geopolitical uncertainty. New developments include a record UK renewables output blunting Middle East war impacts on power prices, a counter-signal to energy inflation fears, and SpaceX targeting a $75 billion IPO, potentially bullish for aerospace and tech. JPMorgan's new CDS basket for AI-debt risk hedging highlights growing credit concerns in financials. The synthesis must note that while oil supply risks are escalating, renewable energy gains and terminal resumptions provide partial offsets, dampening extreme bearish scenarios.